Active substance
Sulfadiazine silver
- SFDA 7
- NHS prices 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| FLAMAZINE CREAM | 1 % | Cream · Topical | 1 Tube | SAR 23.30 | Generic · OTC | RIYADH PHARMA | Valid |
| FLAMAZINE CREAM 1% | 1 % | Cream · Topical | 1 Tube | SAR 34.05 | NCE · OTC | SMITH & NEPHEW PHARMACEUTICALS | Valid |
| FLAMAZINE CREAM 1% | 1 % | Cream · Topical | 1 Tube | SAR 17.30 | NCE · OTC | SMITH & NEPHEW PHARMACEUTICALS | Valid |
| SILVERIN 1% CREAM | 1 % | Cream · Topical | 1 Tube | SAR 4.65 | Generic · OTC | ARAB CENTER FOR PHARMACEUTICALS & CHEMICAL IND. CO. | Withdrawn by regulatory authority · Not Marketed |
| SULPHADIAZINE INJ 27.2%W-V 4ML AMP | 27.2 % | Solution · Intravenous use | 10 Ampoule | SAR 41.95 | NCE · Prescription | AVENTIS PHARMA LIMITED | Withdrawn by MAH · Not Marketed |
| SULPHARGIN | 1 % | Cream · Topical | 1 Tube | SAR 4.20 | Generic · OTC | THE NILE COMPANY FOR PHARMACEUTICALS AND CHEMICAL IND. | Suspended · Not Marketed |
| SULPHARGIN | 1 % | Cream · Topical | 1 Tube | SAR 12.25 | Generic · OTC | THE NILE COMPANY FOR PHARMACEUTICALS AND CHEMICAL IND. | Suspended · Not Marketed |
Indications — CHI Daman Drug Formulary
EPIDERMOLYSIS BULLOSA
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Sulfadiazine silver 1% cream | £18.27 | 500 gram | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Combinations containing Sulfadiazine silver
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.